|
 |
 |
|
|||
|
|||
 |
|||
 |
 |
|||
Abingworth has raised eight funds dedicated to investment in life sciences.
| • | Abingworth Bioventures V raised £300 million in January 2007. This fund is actively investing. |
| • | Abingworth Bioventures IV raised $350 million in August 2003. |
| • | Abingworth Bioventures III raised $225 million in 2001 and made 16 venture investments. This fund is fully invested. |
| • | Abingworth BioEquities is an open-ended fund and Abingworth’s first fund dedicated solely to investments in quoted stocks. |
| • | Previous funds are either fully liquidated or making no new investments. |
Portfolios can be viewed on the Abingworth website: www.abingworth.com
International Investor BaseAbingworth raises its own funds for venture investment mainly from a broad group of international blue chip investors. These include funds of funds, pension funds, endowments, foundations and insurance companies.
Leading Edge CompaniesPast investments have been in areas that include the development of novel therapeutic drugs, for example new approaches to cancer, treatment of neurological diseases, anti-virals, ischaemia and stroke. Abingworth has also invested in companies involved in genomics, vaccines, RNAi and antibodies as well as instrumentation, bioinformatics, medical devices and healthcare services.
Investments have included Alnylam Pharmaceuticals, Aurora Biosciences, Aviron, Devgen, GelTex Pharmaceuticals, Gilead Sciences, Healtheon, IDEC Pharmaceuticals, Neurocrine Biosciences, Pharmion, PowderMed and Solexa.